TerweeCB, DekkerFW, MouritsMP, GerdingMN, BaldeschiL, KalmannR, PrummelMF, WiersingaWM. 2001. Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clin Endocrinol (Oxf), 54:391–398.
PontoKA, MerkesdalS, HommelG, PitzS, PfeifferN, KahalyGJ. 2013. Public health relevance of Graves' orbitopathy. J Clin Endocrinol Metab, 98:145–152.
5.
WangY, SmithTJ. 2014. Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci, 55:1735–1748.
6.
MoshkelgoshaS, SoPW, DeasyN, Diaz-CanoS, BangaJP. 2013. Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves' orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation. Endocrinology, 154:3008–3015.
7.
BartalenaL, KrassasGE, WiersingaW, MarcocciC, SalviM, DaumerieC, BournaudC, StahlM, SassiL, VeronesiG, AzzoliniC, BoboridisKG, MouritsMP, SoetersMR, BaldeschiL, NardiM, CurròN, BoschiA, BernardM, von ArxG. 2012. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. European Group on Graves' Orbitopathy. J Clin Endocrinol Metab, 97:4454–4463.
8.
SalviM, VannucchiG, CurròN, CampiI, CovelliD, DazziD, SimonettaS, GuastellaC, PignataroL, AvignoneS, Beck-PeccozP. 2015. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe graves' orbitopathy: a randomized controlled study. J Clin Endocrinol Metab, 100:422–431.
9.
StanMN, GarrityJA, Carranza LeonBG, PrabinT, BradleyEA, BahnRS. 2015. Randomized controlled trial of rituximab in patients with Graves' orbitopathy. J Clin Endocrinol Metab, 100:432–441.
10.
MarcocciC, KahalyGJ, KrassasGE, BartalenaL, PrummelM, StahlM, AlteaMA, NardiM, PitzS, BoboridisK, SivelliP, von ArxG, MouritsMP, BaldeschiL, BencivelliW, WiersingaW. 2011. Selenium and the course of mild Graves' orbitopathy. N Engl J Med, 364:1920–1931.
11.
PerrosP, ChandlerT, DayanCM, DickinsonAJ, FoleyP, HickeyJ, MacewenCJ, LazarusJH, McLarenJ, RoseGE, UddinJM, VaidyaB. 2012. Orbital decompression for Graves' orbitopathy in England. Eye (Lond), 26:434–437.
12.
PerrosP, WiersingaWM. 2010. The Amsterdam Declaration on Graves' orbitopathy. Thyroid, 20:245–246.
13.
BrettJ, StaniszewskaS, MockfordC, Herron-MarxS, HughesJ, TysallC, SulemanR. 2014. Mapping the impact of patient and public involvement on health and social care research: a systematic review. Health Expect, 17:637–650.
14.
Fight for sight. Available at: www.rcophth.ac.uk/wp-content/uploads/2015/02/Sight-Loss-and-Vision-Priority-Setting-Partnership-FINAL-REPORT.pdf (accessed October7, 2015).
15.
SmithHB, PorteousC, BunceC, BonsteinK, HickeyJ, DayanCM, AdamsG, RoseGE, EzraDG. 2014. Description and evaluation of the first national patient and public involvement day for thyroid eye disease in the United Kingdom. Thyroid, 24:1400–1406.
16.
TEAMED. Available at: www.btf-thyroid.org/index.php/campaigns/teamed (accessed October7, 2015).
17.
European Group on Graves' Orbitopathy. Available at: www.eugogo.eu (accessed October7, 2015).
18.
SackettDL, RichardsonWS, RosenbergW, HaynesRB. 1997. Evidence-Based Medicine: How to Practice and Teach EBM. Churchill Livingston, New York.
19.
PerrosP, ZarkovicM, AzzoliniC, AyvazG, BaldeschiL, BartalenaL, BoschiA, BournaudC, BrixTH, CovelliD, ĆirićS, DaumerieC, EcksteinA, FichterN, FührerD, HegedüsL, KahalyGJ, KonukO, LareidaJ, LazarusJ, LeoM, MathiopoulouL, MenconiF, MorrisD, OkosiemeO, OrgiazziJ, PitzS, SalviM, Vardanian-VartinC, WiersingaW, BernardM, ClarkeL, CurròN, DayanC, DickinsonJ, KneževićM, LaneC, MarcocciC, MarinòM, MöllerL, NardiM, NeohC, Simon PearceS, von ArxG, TörünerFB. 2015. PREGO (Presentation of Graves' Orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. Br J Ophthalmol, 2015May7 [Epub ahead of print]; pii: bjophthalmol-2015-306733. doi: 10.1136/bjophthalmol-2015-306733.
20.
BartalenaL, BaldeschiL, DickinsonAJ, EcksteinA, Kendall-TaylorP, MarcocciC, MouritsMP, PerrosP, BoboridisK, BoschiA, CurròN, DaumerieC, KahalyGJ, KrassasG, LaneCM, LazarusJH, MarinòM, NardiM, NeohC, OrgiazziJ, PearceS, PincheraA, PitzS, SalviM, SivelliP, StahlM, von ArxG, WiersingaWM. 2008. Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid, 18:333–346.
21.
LeoM, MarcocciC, PincheraA, NardiM, MegnaL, RocchiR, LatrofaF, AlteaMA, MazziB, SistiE, ProfiloMA, MarinòM. 2012. Outcome of Graves' orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial. J Clin Endocrinol Metab, 97:E44–E48.
